

Original Article

X-ray Investigation of the Aging Process of Aluminum Hydroxide Adjuvant in Protein-Based Vaccine Formulations Over a Short Period

Mohammad Reza Halvagar^{1*}, Mohammad Zali¹, Sara Zali², Mahdiah Najafi Mobarra³, Samira Bahemat¹

¹ Department of Inorganic Chemistry, Chemistry and Chemical Engineering Research Center of Iran, PO Box 14335-186, Tehran, Iran

² Department of Quality Assurance, Razi Vaccine & Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran.

³ Department of Chemistry, Razi Vaccine & Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran

Article Info:

Received: 16 December 2024

Revised: 17 February 2025

Accepted: 22 February 2025

Keywords:

aging process simulation,
aluminum hydroxide adjuvant,
protein adsorption capacity,
sterilization effects on
adjuvants,
vaccine formulation,
X-ray diffraction (XRD).

ABSTRACT

Nearly a century has passed since Glenney and colleagues introduced aluminum-based adjuvants. Over this extensive period, billions of doses of human and veterinary vaccines incorporating these adjuvants have been produced, ensuring both human health and food security. Aluminum-based adjuvants have played a pivotal role during epidemics, allowing scientists to accelerate vaccine development and save lives. Continuous research conducted by institutions worldwide has substantiated the safety and efficacy of aluminum-based adjuvants, establishing them as the gold standard. Consequently, any new adjuvant must be benchmarked against aluminum-based adjuvants and demonstrate substantial advantages in order to gain regulatory approval. This study aims to investigate the short-term structural and physicochemical changes in aluminum hydroxide in protein-based formulations under thermal treatments at 100°C for 24, 48, and 72 hours. These periods were designed to simulate the aging process that occurs during the storage of adjuvants at room temperature. Specifically, the research examines changes in the physicochemical properties of the adjuvant, including pH fluctuations during these thermal treatments, alterations in the sterilization process, protein adsorption capacity for each sample, particle size distribution, and X-ray diffraction (XRD) patterns. These findings not only enhance our understanding of adjuvant stability in vaccine formulations but also provide valuable insights into determining their optimal shelf life and performance. The study demonstrates that the best storage conditions for the adjuvant, with minimal impact from the aging process, are a low pH (pH=5) and higher ionic strength. It was also confirmed that innovative measures, such as reducing the sterilization cycle, stirring the samples after sterilization, and rapidly cooling them afterward, can prevent crystal growth and even produce smaller particle sizes with higher adjuvant activity. This is significant, as previous studies have reported a decline in adjuvant activity following sterilization.

Corresponding Author:
halvagar@ccerci.ac.ir

<https://orcid.org/0000-0002-8914-0717>

<https://orcid.org/0000-0003-3687-0756>

How to cite this article: Halvagar MR, Zali M, Zali S, Najafi Mobarra M, Bahemat S. X-ray Investigation of the Aging Process of Aluminum Hydroxide Adjuvant in Protein-Based Vaccine Formulations Over a Short Period. *Archives of Razi Institute*. 2025;80(4):1047-1057. DOI: 10.32592/ARI.2025.80.4.1047

1. Introduction

Vaccination is one of the most effective strategies for the prevention and control of infectious diseases, safeguarding the health of billions over several decades. Beyond individual protection, vaccines contribute significantly to reducing mortality rates, particularly among children, and alleviate the burden on healthcare systems worldwide. For instance, vaccines against diseases like measles and polio have led to remarkable declines in childhood mortality and have prevented countless hospitalizations, especially in low-resource regions (1).

Veterinary vaccines have also played a crucial role in controlling animal diseases, especially zoonotic diseases, thereby enhancing food security and reducing human exposure to these pathogens (2). This protection extends to broader economic impacts, as the prevention of disease outbreaks through vaccination reduces healthcare costs, improves population productivity, and stabilizes economies—an effect observed during the COVID-19 pandemic and other significant outbreaks (3). Vaccines consist of two essential components: antigens and adjuvants. Antigens form the biological part of the vaccine, representing the pathogen, enabling the immune system to recognize and prepare to combat the actual pathogen. Adjuvants assist by presenting antigens more effectively to the immune system, thereby enhancing the immune response (4). In many vaccines, especially newer formulations, the immune system may not effectively recognize the antigen without the presence of an adjuvant. Adjuvants make it possible for vaccines to achieve the necessary immunogenicity with smaller amounts of antigens. Additionally, they enhance immune responses through various mechanisms.

The concept of adjuvants in vaccine formulations dates back nearly a century, with the introduction of aluminum salts as the first adjuvants by Glenny et al. (1926) (5). They discovered that aluminum-based compounds could significantly enhance the immune response to diphtheria toxoid, allowing for stronger and longer-lasting immunity with lower doses of antigens. This early finding set the foundation for adjuvant research, highlighting the role of adjuvants in boosting vaccine efficacy and reducing the amount of antigens required for effective immunization. Over time, pathogens have become increasingly complex, and with the emergence of new strains, antigens need to be updated and often made more sophisticated. This

means that today's expectations of adjuvants have far surpassed the initial expectations set by Glenny et al. (1926) (5). However, aluminum-based adjuvants continue to be widely used in numerous vaccines, having maintained their status as the dominant adjuvant over nearly a century, to the point where they are now regarded as the gold standard.


Today, multiple vaccine platforms are available, including inactivated, recombinant, and subunit vaccines. Correspondingly, various types of adjuvants—such as oil-based adjuvants (including water-in-oil (W/O) and oil-in-water (O/W) emulsions), squalene-based adjuvants, saponin adjuvants, and nano-based adjuvants—have been developed. Nevertheless, aluminum-based adjuvants continue to be predominant, even in many modern vaccines. Adjuvant research can be seen as a reservoir for the future and a critical foundation for emergency preparedness. Developing adjuvants enables scientists and vaccine manufacturers to be well prepared when confronted with emerging outbreaks. This readiness was evident during the COVID-19 pandemic, when scientists focused on producing antigens and relied on pre-developed adjuvants to expedite vaccine availability. Notably, among the COVID-19 vaccines developed during the pandemic, those utilizing the inactivated platform predominantly incorporated aluminum-based adjuvants into their formulations.

In summary, the combination of safety, cost-effectiveness, stability, and proven efficacy in stimulating humoral immunity makes aluminum-based adjuvants ideal for many vaccine formulations. While research continues into developing adjuvants that also enhance cellular immunity, aluminum adjuvants remain indispensable in modern vaccination programs, especially for routine and widely administered vaccines. Despite nearly a century of use and research, there are still uncertainties regarding the exact mechanisms of action for aluminum-based adjuvants (6).


Additionally, new adjuvants must demonstrate their efficacy and safety through comparison with aluminum-based adjuvants to receive regulatory approval. These factors make ongoing research into aluminum-based adjuvants essential (7). One of the most well-known mechanisms is the "depot effect," in which aluminum-based adjuvants act as a reservoir, releasing the antigen gradually to elicit a prolonged immune response, reducing the need for additional booster doses. Consequently,

adjuvants must be capable of physically or chemically binding to the antigen and delivering it to antigen-presenting cells following injection.

This binding generally occurs on the antigen's surface, and adjuvant design often aims to establish electrostatic interactions between the adjuvant and the antigen. As such, key characteristics like surface charge (or zeta potential) and surface area, which correspond to adjuvant size, are carefully controlled to optimize this binding. Aluminum hydroxide adjuvants possess an amorphous structure that undergoes sequential deprotonation and dehydration reactions during the aging process (as shown in Eq. 1 and Eq. 2). These reactions lead to the formation of double hydroxide bridges, resulting in the release of H^+ ions (8). Throughout this process, aluminum hydroxide transitions from an amorphous structure to a more crystalline form, such as poorly crystalline boehmite ($AlOOH$).



Eq. 1. Deprotonation reaction during the aging process



Eq. 2. Dehydration reaction during the aging process

The development of double hydroxide bridges enhances the crystallinity and structural order of the material. Aluminum hydroxide, initially in an amorphous state, gradually transitions into a more crystalline form, such as $AlOOH$ with low crystallinity. This structural ordering can be clearly observed in the differences between the XRD patterns of the adjuvants before and after the aging process. Fresh aluminum hydroxide adjuvants exhibit an amorphous structure, resulting in broad and low-intensity peaks in their XRD patterns. Gradually, as the structure of the adjuvant becomes more ordered and transitions into a semi-crystalline form, the peaks become sharper and more intense, while their width decreases.

The width-at-half-height (WHH) can be used as a reliable measure of aging. A lower WHH value indicates a more developed structure of the adjuvant, signifying that the sample has undergone a more extensive aging process (9). The formation of each hydroxide bridge releases protons (H^+) into the environment, leading to a gradual decrease in pH. This change plays a critical role in the aging process and impacts the material's stability.

As structural order increases and hydroxide bridges form, the available active surface area decreases. This reduction adversely affects the material's capacity to adsorb proteins or antigens, which is a key property influencing the performance of adjuvants in vaccine formulations (10). Due to structural changes and increased crystalline order of aluminum hydroxide adjuvants during the aging process, the effective surface area of the adjuvant particles decreases, leading to a reduction in their protein adsorption capacity (11). For this evaluation, bovine serum albumin (BSA), with an isoelectric point of approximately 4.8, is used as the model protein, as the isoelectric point of aluminum hydroxide adjuvant is around 11. Consequently, under near-neutral pH conditions, the adjuvant and the model protein carry opposite charges, creating optimal conditions for assessing protein adsorption (12).

Thus, the aluminum hydroxide adjuvant subjected to the aging process can be evaluated by considering the following factors: monitoring changes in the pH of the undiluted adjuvant over time or during a simulated aging process; examining changes in particle size over time or during a simulated aging process; assessing changes in the adsorption capacity for a model protein over time or during a simulated aging process; and analyzing XRD patterns at the beginning and end of the process.

Given that adjuvants are used in vaccine formulations and are categorized as injectable products, they must be fully sterilized and free of any microorganisms. The most common method for sterilizing adjuvants is steam autoclaving, in which the sample is subjected to a temperature of 121°C for 30 or 60 minutes under 1.2 bar of positive pressure. Consequently, aluminum hydroxide adjuvants synthesized for vaccine formulations inevitably undergo significant aging during the sterilization process. Burrell et al. (1999) (13) reported that if aluminum hydroxide samples are sterilized at 121°C for 30 or 60 minutes, their structure becomes somewhat more ordered. However, they did not observe a significant impact of this limited structural change on protein adsorption capacity. Similar observations were reported by Yu et al. (2023) (14) for Alhydrogel® samples. Nevertheless, it is evident that if milder sterilization conditions are selected, and factors such as zeta potential adjustment, stirring during the process, and rapid cooling after sterilization are utilized, autoclaving can be used as a method to prevent crystal growth in aluminum hydroxide.

The aim of this study was to investigate the aging process of aluminum hydroxide adjuvant, focusing on the changes that occur in key parameters such as pH, particle size, protein adsorption capacity, and XRD patterns. Considering that aging is inherently a long-term process, a thermal treatment method was utilized to simulate aging within a shorter timeframe. By subjecting the adjuvant to controlled heating at 100°C for durations of 24, 48, and 72 hours, this study aimed to replicate the structural and physicochemical changes typically observed during prolonged storage. This approach provides a practical and accelerated model for understanding the factors influencing the stability and functionality of aluminum hydroxide adjuvants.

In this study, aluminum hydroxide adjuvant was subjected to aging simulation at pH levels of 5, 6, 7, and 8, as well as in a solution containing 8.5 g/L sodium chloride with a pH of 7, for durations of 24, 48, and 72 hours at 100°C. Additionally, from each series, one sample was sterilized using steam autoclaving at 121°C for 15 minutes. Immediately after the sterilization cycle, the samples were rapidly cooled with agitation. Subsequently, changes in pH, particle size, and protein adsorption capacity were measured. XRD patterns were obtained for the initial samples, 72-hour-aged samples, and sterilized samples from each series. The results showed that samples maintained at higher pH levels experienced more pronounced structural changes due to the aging process, which was confirmed by the XRD patterns. Similarly, an increase in particle size was observed in the samples that were more significantly affected by aging. A parallel trend was also noted in the reduction of protein adsorption capacity.

Increasing the ionic strength of the adjuvant solution by adding sodium chloride weakens dipole interactions and reduces the zeta potential of particles in these samples. Consequently, the aging process was observed to be significantly slower in samples with higher ionic strength. For the sterilized samples, the reduced sterilization time of 15 minutes and the use of agitation during cooling disrupted crystal growth. This intervention resulted in XRD patterns that were more similar to those of amorphous structures. However, these changes during the sterilization process did not have a significant impact on protein adsorption capacity, and the samples remained within the defined standard limits.

2. Materials and Methods

2.1. Materials

This study utilized an aluminum hydroxide adjuvant produced by the Razi Vaccine and Serum Research Institute (Karaj, Iran), which was prepared and concentrated as a 1.65% solution. BSA was purchased from Merck (Darmstadt, Germany). Additionally, the following chemical compounds were used in the synthesis process:

- An ammonium sulfate, batch number 17465103, purchased from Scharlau, molecular biology grade.
- An aluminum ammonium sulfate (dodecahydrate), batch number 20445101, purchased from Scharlau, extra pure grade.
- An ammonia solution (25%), batch number 3333, purchased from Merck.

2.2 Apparatus

- XRD analysis was performed using a D8 Bruker Advance X-ray Diffractometer.
- Protein adsorption measurements were conducted at a wavelength of 280 nm using a UV-160A Shimadzu UV-Visible Spectrophotometer.
- Particle size determination was carried out using a Zetasizer Nano ZS 90.

2.3. Preparation of Aluminum Hydroxide Gel

To synthesize the aluminum hydroxide adjuvant, an ammonium sulfate solution was first used to create a buffered environment, maintaining the pH between 8 and 9 by adding an ammonium hydroxide solution. Subsequently, with vigorous stirring, an aluminum ammonium sulfate solution was rapidly introduced. The stoichiometric ratios were carefully adjusted to ensure that the final pH of the reaction remained between 7.5 and 8.

After 1 hour of continuous stirring, the mixture was allowed to stand to facilitate the formation of a gel phase, while a clear supernatant layer developed. The next step involved decanting the supernatant liquid to remove excess ammonium sulfate. The gel was then washed until the ammonium ion concentration was reduced to 50 ppm and the sulfate ion concentration was reduced to 100 ppm. Finally, the gel concentration was adjusted to 1.65% dry matter.

2.4. Sampling and Experimental Design

Initially, the primary aluminum hydroxide gel was adjusted to pH levels of 5, 6, 7, and 8, and the samples were coded based on their pH (for example, series 5 refers

to samples with initial pH of 5). Additionally, a sample with a pH of 7 was prepared by adding 8.5 g.L^{-1} of NaCl, and this sample was coded as Z. This sample was specifically prepared to evaluate the effect of increased ionic strength on the aging process.

Considering that the aging process can be simulated by maintaining the samples at 100°C for a specified duration, the samples were stored at this temperature for 24, 48, and 72 hours. Furthermore, one sample from each batch was subjected to steam autoclaving at 121°C for 15 minutes to study the effect of the autoclave process on aging. Immediately after the sterilization cycle, the samples were stirred, and their temperature was rapidly brought down to room temperature. The collected samples were sequentially analyzed for pH changes, particle size variations, BSA adsorption capacity, and finally, their XRD patterns were obtained.

2.5. Sampling and Experimental Design

The primary aluminum hydroxide gel was adjusted to pH levels of 5, 6, 7, and 8, and the samples were coded accordingly (e.g., series 5 refers to samples with an initial pH of 5). Additionally, to evaluate the effect of increased ionic strength, a sample with a pH of 7 containing 8.5 g.L^{-1} of NaCl was prepared and coded as Z.

Since the aging process can be simulated by thermal treatment, the samples were stored at 100°C for 24, 48, and 72 hours. Furthermore, one sample from each batch was subjected to steam autoclaving at 121°C for 15 minutes to evaluate the effect of sterilization on aging. Immediately after the sterilization cycle, the samples were stirred, and their temperature was rapidly brought down to room temperature.

2.6. Analytical Methods

The collected samples were sequentially analyzed for:

1. pH changes
2. Particle size variations
3. BSA adsorption capacity
4. XRD patterns

2.7. Justification for the 72-Hour Aging Study

Aging is a long-term process that occurs over weeks or months in real storage conditions. However, to accelerate and simulate this process in a shorter timeframe, a thermal treatment approach at 100°C was employed for 24, 48, and 72 hours. This method aligns with previous studies in which controlled thermal conditions were used to induce and analyze structural changes in aluminum hydroxide adjuvants (13).

Additionally, this timeframe was selected based on the fact that significant structural transformations, including changes in pH, particle size, and protein adsorption capacity, were observed within this period. However, it is acknowledged that further studies involving longer storage durations under controlled conditions are necessary for a more comprehensive aging profile.

It is important to note that the aging process is inherently a time-dependent phenomenon, but the objective of this study was not to determine the stability or shelf life of the adjuvant. Instead, this research aimed to analyze the aging trends and the structural changes that occur during the process. By studying these trends, valuable insights can be gained into the physicochemical changes that take place and their impact on protein-based vaccine formulations. Furthermore, the study provides a basis for proposing strategies to slow down or even halt the aging process, thereby ensuring better formulation stability and efficacy in vaccine development.

3. Results

3.1. pH Changes Analysis

Figure 1 illustrates the pH changes in different samples after 24, 48, and 72 hours of storage at 100°C . The results indicate that samples with higher initial pH values experience more significant pH changes. These changes can be attributed to the chemical equilibrium of the reaction described in Equation (1). At higher pH levels, the reaction tends to release more H^{+} ions, leading to a greater decrease in pH. Consequently, samples with an initial pH of 8 exhibit the most pronounced pH changes compared to other samples. Comparing the graphs of the Z and 7 series samples (Figure 1) reveals that the pH changes in the Z series samples are slightly more substantial, despite both series having the same initial pH of 7. This discrepancy is likely due to the higher ionic strength in the Z series, which reduces the activity of the H^{+} ions produced during the reaction described in Equation 1. As a result, the reaction proceeds further in the Z series, generating more H^{+} ions and leading to greater pH changes.

An intriguing observation is that in all sample series, the pH changes in the sterilized samples are negligible compared to their initial values (Hour 0). This finding suggests that the autoclaving process under the described conditions significantly slowed the reaction outlined in Equation 1. This slowdown can be attributed to the following factors:

1. The reduced sterilization time of 15 minutes, which limited the extent of the reaction.

2. Continuous agitation during the cooling phase and rapid cooling, which disrupted the crystallization process and preserved the amorphous structure of the samples.

3.2. Particle Size Changes

Figure 2 illustrates the changes in particle size across different samples. As outlined in Equation 1, at higher pH levels, the reaction responsible for forming double hydroxide bridges progresses more rapidly, releasing more H^+ ions. The continuation of this reaction facilitates the formation of additional double hydroxide bridges, which leads to an increase in particle size over time.

When comparing samples Z and 7 series, Figure 1 previously showed that the pH change in sample Z was greater than in sample 7 series, attributed to the reaction described in Equation 1 producing more H^+ ions in the Z series due to its higher ionic strength. However, Figure 2 reveals an interesting trend: the particle size in sample Z is smaller compared to sample 7 series. This apparent discrepancy can be explained by considering the role of ionic strength. In sample Z, the increased ionic strength reduces electrostatic interactions between particles, as described in Equation 2. This reduction slows the rate of particle aggregation and the formation of double hydroxide bridges, despite the higher H^+ ion production observed in sample Z.

These findings highlight the complex interplay between ionic strength, particle aggregation, and reaction progression in the formation of aluminum hydroxide adjuvants. While the progression of the reaction in Equation 1 leads to pH changes and potential particle growth, the influence of ionic strength significantly moderates particle size by mitigating interparticle attractions. This underscores the importance of controlling ionic strength in optimizing adjuvant properties for vaccine formulations.

3.3. Changes in Protein Adsorption Capacity

In this experiment, BSA was used as the model protein due to its isoelectric point of 4.8, in contrast to the isoelectric point of aluminum hydroxide, which is 11. Figure 3 shows the percentage of BSA adsorption at a concentration ratio of one milligram of aluminum to four milligrams of BSA.

As observed in Figures 1 and 2, the effects of the aging process were more pronounced in samples with higher pH. Consequently, aged samples showed a greater loss in protein adsorption capacity compared to non-aged samples. This trend is generally evident in Figure 3, where

samples with lower pH demonstrate a better ability to adsorb proteins.

Interestingly, in sample Z, despite the reduction in particle size, there was no corresponding increase in protein adsorption capacity. This can be attributed to the fact that particle size is only one of the factors influencing protein adsorption. The reduction in electrostatic interactions due to a lower zeta potential in sample Z resulted in diminished protein adsorption capacity. In this context, the increased ionic strength, while moderating particle aggregation as shown earlier, adversely affected protein adsorption by reducing the effective binding forces between the protein molecules and the adjuvant surface. Thus, although sample Z underwent less aging, it exhibited a greater reduction in protein adsorption capacity.

The sterilized samples, as illustrated in Figure 3, retained a significant portion of their initial protein adsorption capacity. Measures taken during sterilization, including reducing the sterilization time and stirring during the cooling phase, were effective in mitigating the aging effects. These interventions disrupted crystallization processes, preserved the surface reactivity of the adjuvant, and thereby maintained its protein adsorption capacity. These findings highlight the intricate balance between ionic strength, surface properties, and protein adsorption in optimizing aluminum hydroxide adjuvants. Maintaining proper ionic conditions and using precise sterilization protocols can significantly enhance the functionality of adjuvants in vaccine formulations.

3.4. XRD Pattern Analysis

In Figure 4, the XRD pattern of freshly synthesized aluminum hydroxide adjuvant, which has undergone minimal aging, is shown in blue, while the XRD pattern of the aged sample is represented in red. The pattern of the aged sample features sharp, high-intensity peaks, indicating an increase in structural order and crystallinity. This pattern closely resembles the XRD profile of $Al(OH)_3$. In contrast, the XRD pattern of the freshly prepared adjuvant shows broad, low-intensity peaks, suggesting that the structure remains disordered. This pattern aligns well with the profile of amorphous aluminum hydroxide.

In Figure 5, the XRD patterns of the samples in the range of 17 to 19.5 degrees 2θ are compared, highlighting the changes in samples subjected to a 72-hour thermal treatment, sterilized samples,




Figure 1. pH Changes Over Time.




Figure 2. Particle Size Over Time.








Figure 3. BSA Adsorption Percent at 280 nm in
1 mg Al³⁺ / 4 mg BSA

Figure 4. XRD pattern of freshly synthesized aluminum hydroxide adjuvant and aged aluminum hydroxide adjuvant.

**A****B****C****D**



E

Figure 5. A) XRD patterns of pH 5 series in the range of 17 to 19.5 degrees 2θ , B) XRD patterns of pH 6 series in the range of 17 to 19.5 degrees 2θ , C) XRD patterns of pH 7 series in the range of 17 to 19.5 degrees 2θ . D) XRD patterns of pH 8 series in the range of 17 to 19.5 degrees 2θ . E) XRD patterns of Z series in the range of 17 to 19.5 degrees 2θ .

and initial samples at the same pH. It is observed that in all samples, sterilization under the described conditions leads to the transformation of the semi-crystalline structure toward an amorphous state. As a result, the peaks in the sterilized patterns are broader and less intense. In the pH 7 sample and the sterilized Z sample, the structure is notably more similar to an amorphous form.

Furthermore, it is observed that thermal treatment across all series results in increased structural order, transforming the samples into a semi-crystalline AlOOH form. Samples with higher pH exhibit greater crystallinity.

4. Discussion

The aging process induces significant structural changes in aluminum hydroxide adjuvants, primarily through the formation of double hydroxide bridges, leading to a decrease in pH and an increase in particle size. These structural changes are clearly observable in XRD patterns. Additionally, the increased structural order and formation of semi-crystalline structures due to aging contribute to reduced protein adsorption capacity, ultimately diminishing the adjuvanticity of the adjuvant. Sterilization, a critical step in vaccine production, poses challenges as it can accelerate aging effects and increase structural ordering, as reported by Barrell et al. (1999) (13) and Yu et al. (2023) (14). However, the innovative strategies employed in this study—such as reducing sterilization time to 15 minutes, continuous agitation during the cooling phase, and rapid cooling post-sterilization—successfully mitigated these aging effects.

These measures disrupted crystallization, preserved the amorphous structure of the adjuvant, and produced finer particles, aligning with methodologies used in nano-adjuvant synthesis.

The findings also revealed that maintaining the adjuvant at a pH of 5 and increasing the ionic strength of the solution effectively reduced crystallization tendencies and preserved adjuvanticity. The minimal pH changes observed in sterilized samples provide compelling evidence for the importance of optimized sterilization protocols. These results highlight that maintaining pH stability is crucial for ensuring the structural integrity of protein-based antigens, minimizing aggregation, and achieving consistent adjuvant performance. Furthermore, the findings align with previous studies, including those by Yu et al. (2023) (14), demonstrating that autoclaving under controlled conditions stabilizes the structure of aluminum hydroxide adjuvants and prevents crystallization. This underscores the critical role of balancing ionic strength and refining sterilization techniques to enhance vaccine stability and performance.

Overall, despite the observed aging effects, aluminum hydroxide adjuvant samples produced under the experimental conditions maintained their quality within defined standards. However, these findings underscore the need for further optimization of storage conditions and handling practices to minimize aging-related reductions in protein adsorption capacity and adjuvant efficacy. This study demonstrated that the aging process significantly affects the structural and physicochemical properties of aluminum hydroxide adjuvants, including reductions in

pH, increases in particle size, and declines in protein adsorption capacity. These changes can adversely impact the adjuvanticity of aluminum hydroxide. Nevertheless, strategies such as reducing sterilization time, increasing ionic strength, and maintaining optimal pH effectively mitigated these effects, preserving the stability and functionality of the adjuvant.

The observed stability of sterilized samples, particularly their minimal pH changes, is a significant finding for vaccine formulations. Maintaining pH stability ensures the integrity of protein antigens, reduces aggregation, and enhances adjuvant performance, ultimately contributing to vaccine efficacy. The alignment of these results with prior research on ionic strength and sterilization (13,14), provides strong evidence for the practical application of these approaches in vaccine development.

Although this study was limited to a 72-hour simulation of aging, it provided valuable insights into short-term structural changes and their implications. Future research should explore the long-term effects of aging under real-world storage conditions to develop a more comprehensive profile of aging. This research enhances our understanding of aluminum hydroxide adjuvants and provides practical solutions for optimizing their performance in protein-based vaccine formulations. These findings can guide the development of more stable and effective vaccine formulations, reinforcing the role of aluminum hydroxide as a gold standard adjuvant in vaccine production.

Acknowledgment

Financial support for this project was provided by the Research Council of Razi Vaccine and Serum Research Institute (RVSRI)

Authors' Contribution

Study concept and design: M. Z.

Acquisition of data: M. Z. And M.N. and M.R.H. and S.Z. and S.B.

Analysis and interpretation of data: M. Z. and M.R.H and S.Z.

Drafting of the manuscript: M. Z.

Critical revision of the manuscript for important intellectual content: M. Z. and M.R.H. and S.Z.

Administrative, technical, and material support: M.R.H.

Study supervision: M. Z. and M.R.H.

Ethics Statement

This study did not involve any experiments on humans or animals. Therefore, ethical approval was not required.

Conflict of Interest

The authors declare that they have no conflicts of interest relevant to the content of this article.

Funding / Grant Support

This work was carried out using the research infrastructure and laboratory facilities of the Iranian Research Institute of Chemical Engineering and the Razi Vaccine and Serum Research Institute (RVSRI). No dedicated financial grant was received from governmental, commercial, or non-profit funding agencies. The study was supported institutionally through access to laboratory equipment and technical resources.

Data Availability

All data generated or analyzed during this study are available from the corresponding author upon reasonable request.

References

1. World Health Organization (WHO). Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO [Internet]. 2024. Available from: <https://www.who.int/news/item/31-01-2024-message-by-the-director-of-the-department-of-immunization>
2. World Health Organization (WHO). Counting the impact of vaccines: For a safer, healthier world [Internet]. 2021. Available from: <https://www.who.int/news/item/22-04-2021-counting-the-impact-of-vaccines>
3. Centers for Disease Control and Prevention (CDC). Vaccine-Preventable Diseases. Global Immunization Strategic Framework [Internet]. 2024. Available from: <https://www.cdc.gov/globalhealth/immunization>
4. Wang Z, Li S, Shan P, Wei D, Hao S, Zhang Z, Xu J. Improved aluminum adjuvants eliciting stronger immune response when mixed with hepatitis B virus surface antigens. *ACS Omega*. 2022;7:34528-34537.

5. Glenny AT, Pope CG, Waddington H, Wallace U. Immunological notes. XVII–XXIV. J Pathol Bacteriol. 1926;29:31–40.
6. Ghimire TR. The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm. SpringerPlus. 2015;4:181. doi:10.1186/s40064-015-0972-0.
7. Laera D, HogenEsch H, O'Hagan DT. Aluminum Adjuvants—'Back to the Future.' Vaccines. 2022;10(7):1099. doi:10.3390/vaccines10071099.
8. Burrell LS, White JL, Hema SL. Stability of aluminium-containing adjuvants during aging at room temperature. Vaccine. 2000;18(21):2188-2192.
9. Yau KP, Schulze DG, Johnston CT, Hem SL. Aluminum hydroxide adjuvant produced under constant reactant concentration. J Pharm Sci. 2006;95(12):2731-2738. doi:10.1002/jps.20692.
10. Johnston CT, Wang SL, Hem SL. Measuring the surface area of aluminum hydroxide adjuvant. J Pharm Sci. 2002;91(7):1703-1711. doi:10.1002/jps.10141.
11. Dandashli EA, Zhao Q, Yitta S, Morefield GL, White JL, Hem SL. Effect of thermal treatment during the preparation of aluminum hydroxide adjuvant on the protein adsorption capacity during aging. Pharm Dev Technol. 2002;7(4):401-406.
12. Rinella JV Jr, White JL, Hem SL. Effect of anions on model aluminum adjuvant-containing vaccines. J Colloid Interface Sci. 1998;205:161–165.
13. Burrell LS, Lindblad EB, White JL, Hem SL. Stability of aluminium-containing adjuvants to autoclaving. Vaccine. 1999 Jun 4;17(20-21):2599-603. doi: 10.1016/s0264-410x(99)00051-1.
14. Yu G, Yang W, Zhang N, Yang C, Zeng H, Xue C, Sun B. Autoclave-Induced Changes in the Physicochemical Properties and Antigen Adsorption of Aluminum Adjuvants. Pharmaceutical Nanotechnology. 2023. doi:https://doi.org/10.1016/j.xphs.2023.10.009.